keyword
MENU ▼
Read by QxMD icon Read
search

radioactive iodine refractory

keyword
https://www.readbyqxmd.com/read/28382170/obatoclax-and-ly3009120-efficiently-overcome-vemurafenib-resistance-in-differentiated-thyroid-cancer
#1
Wei-Jun Wei, Zhen-Kui Sun, Chen-Tian Shen, Hong-Jun Song, Xin-Yun Zhang, Zhong-Ling Qiu, Quan-Yong Luo
Although the prognosis of differentiated thyroid cancer (DTC) is relatively good, 30-40% of patients with distant metastases develop resistance to radioactive iodine therapy due to tumor dedifferentiation. For DTC patients harboring BRAF(V600E) mutation, Vemurafenib, a BRAF kinase inhibitor, has dramatically changed the therapeutic landscape, but side effects and drug resistance often lead to termination of the single agent treatment. In the present study, we showed that either LY3009120 or Obatoclax (GX15-070) efficiently inhibited cell cycle progression and induced massive death of DTC cells...
2017: Theranostics
https://www.readbyqxmd.com/read/28335429/the-adverse-effect-of-hypertension-in-the-treatment-of-thyroid-cancer-with-multi-kinase-inhibitors
#2
REVIEW
Ole Vincent Ancker, Markus Wehland, Johann Bauer, Manfred Infanger, Daniela Grimm
The treatment of thyroid cancer has promising prospects, mostly through the use of surgical or radioactive iodine therapy. However, some thyroid cancers, such as progressive radioactive iodine-refractory differentiated thyroid carcinoma, are not remediable with conventional types of treatment. In these cases, a treatment regimen with multi-kinase inhibitors is advisable. Unfortunately, clinical trials have shown a large number of patients, treated with multi-kinase inhibitors, being adversely affected by hypertension...
March 14, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28318881/targeted-therapy-in-thyroid-cancer-state-of-the-art
#3
L Valerio, L Pieruzzi, C Giani, L Agate, V Bottici, L Lorusso, V Cappagli, L Puleo, A Matrone, D Viola, C Romei, R Ciampi, E Molinaro, R Elisei
Thyroid cancer typically has a good outcome following standard treatments, which include surgery, radioactive iodine ablation for differentiated tumours and treatment with thyrotropine hormone-suppressive levothyroxine. Thyroid cancers that persist or recur following these therapies have a poorer prognosis. Cytotoxic chemotherapy or external beam radiotherapy has a low efficacy in these patients. 'Target therapy' with tyrosine kinase inhibitors (TKIs) represent an important therapeutic option for the treatment of advanced cases of radioiodine refractory (RAI-R) differentiated thyroid cancer (DTC), medullary thyroid cancer (MTC) and possibly for cases of poorly differentiated (PDTC) and anaplastic thyroid cancer (ATC)...
March 16, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28270435/timing-of-multikinase-inhibitor-initiation-in-differentiated-thyroid-cancer
#4
Marcia S Brose, Jan Wa Smit, Chia-Chi Lin, Fabian Pitoia, Marc Fellous, Yoriko DeSanctis, Martin Schlumberger, Masayuki Tori, Iwao Sugitani
There are limited treatment options for patients with radioactive iodine-refractory, progressive differentiated thyroid cancer. Although there is consensus that multikinase inhibitor therapy should be considered in patients with progressive disease with considerable tumor load or symptomatic disease, uncertainty exists on the optimal timing to treat with a multikinase inhibitor, especially for asymptomatic patients. RIFTOS MKI is an international, prospective, open-label, multicenter, noninterventional study with the primary objective to compare the time to symptomatic progression from study entry in asymptomatic patients with radioactive iodine -refractory, progressive differentiated thyroid cancer for whom there is a decision to initiate multikinase inhibitors at study entry (cohort 1) with those for whom there is a decision to not initiate multikinase inhibitors at study entry (cohort 2)...
March 7, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28225999/radioactive-iodine-refractory-differentiated-thyroid-cancer-an-uncommon-but-challenging-situation
#5
Angelica Schmidt, Laura Iglesias, Michele Klain, Fabián Pitoia, Martin J Schlumberger
Radioiodine (RAI)-refractory thyroid cancer is an uncommon entity, occurring with an estimated incidence of 4-5 cases/year/million people. RAI refractoriness is more frequent in older patients, in those with large metastases, in poorly differentiated thyroid cancer, and in those tumors with high 18-fluordeoxyglucose uptake on PET/CT. These patients have a 10-year survival rate of less than 10%. In recent years, new therapeutic agents with molecular targets have become available, with multikinase inhibitors (MKIs) being the most investigated drugs...
January 2017: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28141684/treatment-and-surveillance-of-advanced-metastatic-iodine-resistant-differentiated-thyroid-cancer
#6
Eiman Y Ibrahim, Naifa L Busaidy
PURPOSE OF REVIEW: This review will focus on the management and treatment of metastatic thyroid cancer that is radioactive iodine refractory and review the new drugs and their mechanism of actions as well as their adverse events. RECENT FINDINGS: Until recently, there were no efficacious therapeutic modalities for these patients. With advancement in knowledge and research of the molecular aberrations and oncogenic mutations in thyroid cancer as well as further understanding the role of angiogenesis in tumor growth molecular pathogenesis, novel targeted therapies are available for these patients...
March 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28088233/successful-recovery-from-a-subclavicular-ulcer-caused-by-lenvatinib-for-thyroid-cancer-a-case-report
#7
Morimasa Kitamura, Tomomasa Hayashi, Chiaki Suzuki, Shigeru Hirano, Ichiro Tateya, Yo Kishimoto, Koichi Omori
BACKGROUND: There are currently no effective therapeutic methods for locally recurrent, metastatic, or progressive radioactive iodine (RAI)-refractory differentiated thyroid cancer. However, multitargeted tyrosine kinase inhibitors (TKIs) such as lenvatinib or sorafenib have been approved for patients with RAI-refractory differentiated thyroid cancer as a second targeted therapy, and these agents can prolong patient survival. However, several cases have been reported that TKIs have caused fatal complications such as fistula formation or bleeding...
January 14, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28055301/autophagy-orchestrates-adaptive-responses-to-targeted-therapy-in-endometrial-cancer
#8
Núria Eritja, Bo-Juen Chen, Ruth Rodríguez-Barrueco, Maria Santacana, Sònia Gatius, August Vidal, Maria Dolores Martí, Jordi Ponce, Laura Bergadà, Andree Yeramian, Mario Encinas, Joan Ribera, Jaume Reventós, Jeff Boyd, Alberto Villanueva, Xavier Matias-Guiu, Xavier Dolcet, David Llobet-Navàs
Targeted therapies in endometrial cancer (EC) using kinase inhibitors rarely result in complete tumor remission and are frequently challenged by the appearance of refractory cell clones, eventually resulting in disease relapse. Dissecting adaptive mechanisms is of vital importance to circumvent clinical drug resistance and improve the efficacy of targeted agents in EC. Sorafenib is an FDA-approved multitarget tyrosine and serine/threonine kinase inhibitor currently used to treat hepatocellular carcinoma, advanced renal carcinoma and radioactive iodine-resistant thyroid carcinoma...
March 4, 2017: Autophagy
https://www.readbyqxmd.com/read/27972383/efficacy-and-safety-profile-of-lenvatinib-and-sorafenib-in-the-treatment-of-adult-patients-with-advanced-radioactive-iodine-refractory-differentiated-thyroid-cancer-rr-dtc
#9
P Kawalec
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27793633/use-of-177-lu-dotatate-in-the-treatment-of-iodine-refractory-thyroid-carcinomas
#10
P Oliván-Sasot, M Falgás-Lacueva, J García-Sánchez, V Vera-Pinto, C Olivas-Arroyo, P Bello-Arques
In a patient with a differentiated thyroid cancer the standard treatment protocol to be followed is surgery, ablation of thyroid remnants with (131)Iodine ((131)I), and TSH suppression. However, the treatment with (131)I is not effective in some cases, and it no longer becomes a therapeutic option due to cell de-differentiation with loss of (131)I uptake. Systemic treatment can be used as other options, although patients are not always responsive; thus, the disease may progress and therapeutic options may run out...
October 25, 2016: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/27741354/2015-american-thyroid-association-management-guidelines-for-adult-patients-with-thyroid-nodules-and-differentiated-thyroid-cancer-what-is-new-and-what-has-changed
#11
Bryan R Haugen
Thyroid nodules are very common, and thyroid cancer is currently the fifth leading cancer diagnosis in women. The American Thyroid Association has led the development and revision of guidelines for the management of patients with thyroid nodules and differentiated thyroid cancer (DTC). The most current revision was published in the January 2016 issue of the journal Thyroid. The current guidelines have 101 recommendations, with 8 figures and 17 tables that are hopefully helpful to those treating patients with thyroid nodules and cancer...
February 1, 2017: Cancer
https://www.readbyqxmd.com/read/27734713/lenvatinib-for-the-treatment-of-radioiodine-refractory-differentiated-thyroid-carcinoma-a-systematic-review-and-indirect-comparison-with-sorafenib
#12
REVIEW
Pawel Kawalec, Iwona Malinowska-Lipień, Tomasz Brzostek, Maria Kózka
Thyroid carcinoma is the most prevalent endocrine malignancy, with an increasing incidence over the past decades. Treatment of differentiated thyroid cancer consists of surgery followed by radioactive iodine (RAI) ablation of the thyroid remnant, and TSH suppression. Among new therapeutic solutions for patients with advanced RR-DTC stage, the most promising seem to be sorafenib and lenvatinib, up to now considered to be orphan drugs. Areas covered: We performed a systematic review of medical databases to collect all eligible clinical trials referring to the topic of our analysis...
December 2016: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/27704399/consensus-on-the-management-of-advanced-radioactive-iodine-refractory-differentiated-thyroid-cancer-on-behalf-of-the-spanish-society-of-endocrinology-thyroid-cancer-working-group-gtseen-and-spanish-rare-cancer-working-group-gethi
#13
REVIEW
J Capdevila, J C Galofré, E Grande, C Zafón Llopis, T Ramón Y Cajal Asensio, E Navarro González, P Jiménez-Fonseca, J Santamaría Sandi, J M Gómez Sáez, G Riesco Eizaguirre
Thyroid cancer is the single most prevalent endocrine malignancy; differentiated thyroid cancer (DTC) accounts for more than 90 % of all malignancies and its incidence has been rising steadily. For more patients, surgical treatment, radioactive iodine (RAI) ablation, and thyroid-stimulating hormone (TSH) suppressive therapy achieve an overall survival (OS) rate of 97.7 % at 5 years. Nevertheless, locoregional recurrence occurs in up to 20 % and distant metastases in approximately 10 % at 10 years. Two-thirds of these patients will never be cured with radioactive iodine therapy and will become RAI-refractory, with a 3-year OS rate of less than 50 %...
March 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27614988/multitargeted-kinase-inhibition-in-metastatic-differentiated-radioiodine-refractory-thyroid-cancer-a-look-at-new-therapeutic-options-for-a-rare-disease
#14
REVIEW
Katharina Mischler, Stefan Kneifel, Richard Cathomas
BACKGROUND: Metastatic differentiated thyroid cancer (DTC) is a rare disease that is in the first line treated with iodine-131 radioisotope therapy. Until recently, options were very limited in the case of progressive radioactive-iodine (RAI)-refractory disease. Based on new study results, tyrosine kinase inhibitors (TKIs) have attracted attention. The TKI sorafenib demonstrated significantly improved progression-free survival (PFS) in a phase III trial. Recent data from another phase III trial showed that the TKI lenvatinib achieved high response rates and a large improvement in PFS in metastatic RAI-refractory DTC patients in the first-line setting and after 1 prior line of TKI...
2016: Oncology Research and Treatment
https://www.readbyqxmd.com/read/27554612/vemurafenib-active-in-iodine-refractory-thyroid-cancer
#15
(no author information available yet)
A new study shows that the BRAF inhibitor vemurafenib may induce partial responses and stable disease in patients with papillary thyroid cancer that has become refractory to radioactive iodine. However, the drug led to a variety of serious adverse events in roughly 65% of patients, including the development of some squamous cell carcinomas.
October 2016: Cancer Discovery
https://www.readbyqxmd.com/read/27493271/tert-promoter-mutation-predicts-radioiodine-refractory-character-in-distant-metastatic-differentiated-thyroid-cancer
#16
Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng, Yansong Lin
Telomerase reverse transcriptase (TERT) promoter mutation has been reported to be associated with aggressive characteristics in differentiated thyroid cancer (DTC). This study examined the status of TERT mutation in distant metastatic DTC and evaluated the correlation between TERT mutation and radioiodine uptake, as well as that between TERT mutation and therapy response. METHODS: TERT promoter and B-Raf proto-oncogene (BRAF) V600E mutation were retrospectively examined in primary tumors of 66 patients with distant metastatic DTC...
February 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27460442/vemurafenib-in-patients-with-braf-v600e-positive-metastatic-or-unresectable-papillary-thyroid-cancer-refractory-to-radioactive-iodine-a-non-randomised-multicentre-open-label-phase-2-trial
#17
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman
BACKGROUND: About half of patients with papillary thyroid cancer have tumours with activating BRAF(V600E) mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF-positive melanoma, showed clinical benefit in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial. We aimed to establish the activity of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer. METHODS: We did an open-label, non-randomised, phase 2 trial at ten academic centres and hospitals worldwide in patients aged 18 years or older with histologically confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodine and positive for the BRAF(V600E) mutation...
September 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27313476/treatment-patterns-health-state-and-health-care-resource-utilization-of-patients-with-radioactive-iodine-refractory-differentiated-thyroid-cancer
#18
Andrew G Gianoukakis, Natalia M Flores, Corey L Pelletier, Anna Forsythe, Gregory R Wolfe, Matthew H Taylor
BACKGROUND: Patients with differentiated thyroid cancer (DTC) often respond well to treatment but some become refractory to radioactive iodine (RAI) treatment, and treatment options are limited. Despite the humanistic and economic burden RAI refractory disease imposes on patients, published research concerning treatment patterns and health care resource utilization is sparse. METHODS: Data were collected from an online retrospective chart review study in the US and five European Union (EU) countries (France, Germany, Italy, Spain, and UK) with physicians recruited from an online panel...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27210070/tyrosine-kinase-inhibitors-to-treat-radioiodine-refracted-metastatic-or-recurred-and-progressive-differentiated-thyroid-carcinoma-review
#19
REVIEW
Yasuhiro Ito, Shinichi Suzuki, Ken-Ichi Ito, Tsuneo Imai, Takahiro Okamoto, Hiroya Kitano, Iwao Sugitani, Kiminori Sugino, Hidemitsu Tsutsui, Hisato Hara, Akira Yoshida, Kazuo Shimizu
Differentiated thyroid carcinoma (DTC) is generally indolent in nature and, even though it metastasizes to distant organs, the prognosis is normally excellent. In contrast, the overall survival (OS) of patients with radioactive iodine (RAI)-refractory and progressive metastases is dire, because no effective therapies have been available to control the metastatic lesions. However, recently, administration of tyrosine-kinase inhibitors (TKIs) has become a new line of therapy for RAI-refractory and progressive metastases...
July 30, 2016: Endocrine Journal
https://www.readbyqxmd.com/read/27202184/estimating-the-economic-impact-of-sorafenib-in-treatment-of-locally-recurrent-or-metastatic-progressive-differentiated-thyroid-carcinoma-dtc-that-is-refractory-to-radioactive-iodine-rai-treatment
#20
M Sussman, M Munsell, A Valderrama, B S Seal, L Wen
No abstract text is available yet for this article.
November 2014: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
117482
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"